semaglutide oral dissolvable film (BNT24005) / BioNxt - LARVOL DELTA

BioNxt Solutions Inc…is pleased to announce the successful completion of proof-of-concept trials for its Semaglutide oral dissolvable film (“ODF“) program at Vektor Pharma TF GmbH (“Vektor Pharma“), the Company’s wholly owned German subsidiary. (ACCESS Newswire) - "The prototypes demonstrated rapid disintegration, homogeneous film quality, good processability during manufacturing, and favorable mechanical properties. These results confirm the suitability of BioNxt's thin film technology for complex peptide formulations and provide a solid foundation for further development...BioNxt is preparing to file a patent application for the Semaglutide ODF in the coming months...These efforts are expected to continue through late 2025 and will culminate in a preclinical animal study anticipated to begin in early 2026."

Preclinical • Obesity • Type 2 Diabetes Mellitus

BioNxt Launches Feasibility Study for Semaglutide Oral Thin Film as Alternative to Injection/Tablets (ACCESSWIRE) - "BioNxt Solutions Inc...is pleased to announce the launch of a feasibility study for the development of an oral dissolvable film (ODF) formulation of Semaglutide, a GLP-1 receptor agonist currently marketed globally under the brand names Ozempic, Rybelsus, and Wegovy. This initiative marks a significant step in evaluating BioNxt's proprietary thin film drug delivery platform as a non-invasive, user-friendly alternative to injectable and tablet-based GLP-1 therapies. The study is designed to assess the compatibility of Semaglutide with BioNxt's ODF technology and generate early data to inform formulation optimization and intellectual property strategy."

Clinical • Obesity • Type 2 Diabetes Mellitus